FDA approvals: Zenbexus, Saphnelo and MRESVIA lead the Aug. 7–14 ledger (2026)

At a glance

The FDA record for August 7 at 5:00 p.m. through August 14 at 5:00 p.m. UTC-05:00 has one clear new-drug lead: Bristol Myers Squibb’s accelerated approval of Zenbexus (iberdomide) for a defined relapsed multiple-myeloma population. Two other actions matter for practice but should not be counted as new disease launches: AstraZeneca’s Saphnelo label now supports subcutaneous dosing, while Moderna’s MRESVIA label adds pediatric safety information about an observed RSV disease imbalance. 1 2 3

The official device files need a warning label. The captured FDA 510(k) and PMA materials in this run contain decision dates only through July 31, so they do not establish a complete August 7–14 device ledger. Three companies announced 510(k) clearances during the window; they are reported separately as a company-announced watchlist, pending confirmation in the FDA-ledger view. 4 5

Action	Date	Population or use	Immediate read
Zenbexus (iberdomide) — Bristol Myers Squibb	Aug. 13	Adults with multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory agent	Accelerated approval for a new oral immunomodulatory component in a daratumumab-based regimen; ZENBEXUS REMS applies.
Saphnelo (anifrolumab-fnia), SUPPL-12 — AstraZeneca	Aug. 7	Adults with moderate-to-severe SLE receiving standard therapy	Subcutaneous 120 mg once weekly added alongside the existing IV option; no new disease population.
MRESVIA — ModernaTX	Aug. 7	RSV vaccine label for adults; new Section 8.4 pediatric safety text	Safety-label update describing an observed imbalance in severe or hospitalized RSV lower-respiratory-tract disease in a narrow infant subgroup; not a pediatric indication.
Hepzato, Opdivo, Winrevair, Meropenem and others	Aug. 10–12	REMS, postmarketing data, long-term safety, administration and labeling changes	Important implementation actions, but not new indications in the evidence reviewed.
Ceribell, DEXTER and pVasc NET	Aug. 10–13	Critical-care EEG software; ventral-hernia robotics; peripheral thrombectomy	Company-announced 510(k) watchlist, not yet reconciled to the captured official FDA files.

New drug approval

Zenbexus: a narrower multiple-myeloma launch with a high evidence bar

FDA granted accelerated approval on August 13 to iberdomide, branded Zenbexus, from Bristol Myers Squibb. The approved combination is iberdomide with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. The label is therefore a post-treatment-line decision, not a broad first-line multiple-myeloma approval. 1

The pivotal evidence came from EXCALIBER-RRMM (NCT04975997), a randomized, multicenter, open-label trial in adults with relapsed or refractory disease after one or two prior lines. In the primary efficacy population of 420 patients, the rate of minimal-residual-disease-negative complete response was 41% with iberdomide plus daratumumab/hyaluronidase and dexamethasone, versus 21% with daratumumab/hyaluronidase, bortezomib and dexamethasone; the FDA reports a p-value below 0.0001. Patients whose disease was refractory to a prior anti-CD38 antibody or bortezomib were excluded, which matters when translating the headline result to later-line practice. 1

The practical regimen is oral iberdomide 1 mg once daily on Days 1–21 of a 28-day cycle, with the other agents administered on their own schedules. The prescribing information carries a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism. Neutropenia, infections and secondary primary malignancies are additional warnings, and dispensing is restricted through the ZENBEXUS Risk Evaluation and Mitigation Strategy. 1

FDA also lists priority review, breakthrough-therapy and orphan-drug designations, and says the review was conducted through Project Orbis with Swissmedic. Those designations explain the development and review pathway; they do not by themselves establish a larger commercial market or a superior clinical outcome. 1

Commercial read. The approval places BMS into an existing, crowded multiple-myeloma treatment sequence rather than opening an unserved mass market. The addressable population is the subset that has already seen both a proteasome inhibitor and an immunomodulatory agent and remains eligible for the trial-like daratumumab-based combination. FDA has not supplied a market-size estimate, launch price or reimbursement category in the approval notice. No independently verifiable peak-sales guidance or contemporaneous analyst revision was identified in the sources reviewed.

For clinicians, the diligence question is whether the response-depth signal fits a patient’s prior exposure and whether the thromboembolism, cytopenia, infection and reproductive-risk controls can be integrated into the existing regimen. For investors, the first observable milestones are REMS and specialty-distribution execution, payer placement, actual treatment-line uptake and the confirmatory evidence required to convert an accelerated approval into durable benefit. The agency’s response metric is meaningful, but it is not the same as an overall-survival result. 1

Administration and access label change

Saphnelo: the same SLE population, a different delivery pathway

Drugs@FDA records an August 7 approval of SUPPL-12 for AstraZeneca’s Saphnelo (anifrolumab-fnia). The updated label keeps the indication unchanged: treatment of adults with moderate-to-severe systemic lupus erythematosus who are receiving standard therapy. It still says efficacy has not been evaluated in severe active lupus nephritis or severe active central-nervous-system lupus, and use is not recommended in those settings. 2 6

The material change is route and workflow. The label now lists 300 mg by IV infusion every four weeks or 120 mg by subcutaneous injection once weekly, with a prefilled syringe and an autoinjector/Saphnelo Pen. That creates a home-administration or lower-infusion-burden option only within the healthcare-provider guidance in the label; it is not evidence that the drug can be used without clinical oversight. 6

The subcutaneous evidence came from Trial 5 (NCT04877691), a 52-week randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe SLE on standard therapy. Patients with severe active lupus nephritis or severe active CNS lupus were excluded. At the interim analysis, BICLA response at Week 52 was 58.5% with weekly subcutaneous Saphnelo versus 43.2% with placebo, a 15.3-percentage-point difference with a reported p-value of 0.0231. 6

Commercial read. This is an access and site-of-care expansion, not an indication-led market-size event. The competitive question is less about adding another SLE mechanism than about whether patients and prescribers value weekly self-injection, whether payers reimburse the product consistently across pharmacy and medical benefits, and whether the new route shifts administration away from infusion centers. The reviewed FDA materials do not disclose a price, net cost, addressable-population estimate or company peak-sales guidance for the subcutaneous presentation.

For clinics, the operational comparison is straightforward: weekly injection supplies and training versus a four-weekly infusion visit. The safety baseline does not disappear with the route; the label continues to warn about serious infection, herpes zoster, hypersensitivity, malignancy and live vaccines. Patients should not interpret a new device presentation as a new indication or as proof that severe renal or CNS disease was studied. 6

Safety and labeling actions

MRESVIA: a pediatric safety signal added to an adult vaccine label

FDA’s August 7 MRESVIA supplement approves a Package Insert update based on an interim analysis of Study mRNA-1365-P101, a postmarketing requirement from the vaccine’s June 14, 2024 approval letter. The new Section 8.4 text describes an observed imbalance in severe and/or hospitalized RSV lower-respiratory-tract disease among participants vaccinated from 5 through 7 months of age who were RSV-seronegative at baseline. 7

MRESVIA’s listed indication remains active immunization to prevent RSV lower-respiratory-tract disease in people 60 and older, and in adults 18–59 at increased risk. The action therefore adds pediatric risk information to an adult product record; it does not authorize routine infant vaccination. The approval letter, as reviewed here, does not provide a public denominator or effect estimate for the imbalance, so the signal should not be converted into a relative-risk claim. 3

Commercial read. For Moderna, this is a safety-surveillance and label-management event, not an adult indication expansion. The relevant commercial variables remain adult recommendation, seasonal supply, payer and pharmacy access, and confidence in the platform. No price, reimbursement change, analyst revision or institutional investor commentary tied specifically to this supplement was verified.

Other captured actions worth tracking

The Drugs@FDA Recent New and Generic Drug Approvals report lists final or tentative original and supplemental actions, but warns that some approvals can enter the database after the displayed period and directs readers to the monthly report for completeness. Within the August 7–13 records, the named actions below are the ones with the clearest clinical, operational or regulatory significance. 8

Product and sponsor	Date / action	What changed	Commercial or clinical interpretation
Hepzato (melphalan) — Delcath Systems	Aug. 12, SUPPL-18, REMS	Adds a web-based dispense-authorization process, clarifies that an NPI is optional for perfusionists on specified forms, and adds fields for percutaneous hepatic-perfusion cycles. 9	A workflow and compliance change. It may reduce administrative friction, but the letter does not expand the indication or establish a larger market.
Opdivo (nivolumab) — Bristol Myers Squibb	Aug. 12, SUPPL-138	Adds updated overall-survival data from the final analysis of CheckMate 816 and fulfills the related postmarketing commitment; the letter notes another commitment remains open. 10	Evidence maintenance and commitment closure, not a new indication in the reviewed action.
Winrevair (sotatercept-csrk) — Merck	Aug. 12, SUPPL-13	Updates the “Uncontrolled Long-term Safety Data” subsection in Section 6.1. 11	A safety-information update that clinicians should fold into monitoring; no indication expansion shown.
Meropenem for injection — HQ Specialty Pharma	Aug. 10, SUPPL-1	Adds direct reconstitution with 0.9% sodium chloride or 5% dextrose, revises stability/storage information and corrects “sodium bicarbonate” to “sodium carbonate.” 12	Practical hospital-pharmacy flexibility rather than a new therapeutic claim.
Fidaxomicin — Sandoz; Fosfomycin tromethamine — Novitium Pharma	Aug. 13 and Aug. 12, ORIG-1	New generic application approvals appear in the FDA feed. 8	Potential competition and supply options, but the feed alone does not establish launch timing, price or market share.
Iqirvo — Ipsen; Krystexxa — Horizon; Durezol — Sandoz; Rimactane — Oxford; plus other ANDA labeling/CMC actions	Aug. 7–12	FDA feed records labeling, Medication Guide, manufacturing or other supplemental actions; the public extract does not support treating these as new indications. 8	Keep these in the regulatory-throughput ledger, not the launch ledger. Item-level commercial effects require the underlying label or company disclosure.

Device ledger

Official FDA capture: incomplete for this window

The FDA 510(k) final-decisions page and the downloadable 2026 materials captured for this issue were updated in early August but contained decision dates only through July 31. The PMA materials reviewed likewise did not expose a decision dated August 7–14. That is a data-latency finding, not evidence that no device decisions occurred. The official ledger will need a later refresh before these dates can be treated as complete. 4 5

Company-announced watchlist

These announcements are useful commercial signals but are not substituted for the FDA database record.

Device and company	Announcement	Intended use / positioning	Commercial read
Neurology Portal AI enhancements — Ceribell	Aug. 10	Company says FDA cleared two 510(k) software enhancements: epileptiform-abnormality detection and artifact reduction for its cloud-based EEG portal. 13	This is an upsell and workflow-efficiency signal on an installed platform, not a new hardware market. Ceribell cites more than one million hours of EEG data, but that is company-reported and not an independent adoption measure.
DEXTER Robotic Surgery System — Distalmotion	Aug. 13	Company says 510(k) clearance adds ventral-hernia repair to the U.S. indications; its stated U.S. intended uses include laparoscopic inguinal and ventral hernia repair, cholecystectomy, benign hysterectomy including salpingo-oophorectomy, and sacrocolpopexy in adults. 14	The company cites more than 600,000 annual ventral-hernia repairs, with more than 75% ambulatory, and says the combined four-procedure portfolio exceeds three million annual U.S. procedures. Those are company-cited market-volume figures, not a forecast of robot placements or revenue.
pVasc NET — Vesalio	Aug. 12–13 announcement	The company announced 510(k) clearance for a peripheral mechanical-thrombectomy device with an integrated distal filter. 15	The announcement points to an embolic-protection and thrombectomy positioning, but the accessible source did not expose the full FDA intended-use statement or a verified market-size/pricing signal. Treat it as a watch item until the FDA record is visible.

What matters next

Zenbexus: watch REMS activation, payer placement, treatment-line adoption and the confirmatory program behind the accelerated approval; do not translate the MRD-negative response difference directly into survival or peak sales.
Saphnelo: watch whether weekly subcutaneous delivery changes infusion-center utilization, payer benefit design or patient persistence without eroding safety monitoring.
MRESVIA: follow the completed pediatric postmarketing analysis and the agency’s interpretation of the imbalance; the current letter supplies a warning-label fact, not a quantified risk estimate.
Devices: refresh the FDA 510(k) and PMA exports before treating Ceribell, DEXTER or pVasc NET as official weekly ledger entries.
Markets: no reliable contemporaneous analyst-rating change, institutional commentary or approval-specific price reaction was verified for this issue. The evidence supports regulatory and workflow analysis, not a trading conclusion.